Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-08-26
Last Posted Date
2011-09-05
Lead Sponsor
Inje University
Target Recruit Count
203
Registration Number
NCT00741286
Locations
🇰🇷

Wonju Christian Hospital, Wonju, Korea, Republic of

🇰🇷

Sanbon Medical Center, Gunpo, Korea, Republic of

🇰🇷

Ajou University Hospital, Suwon, Korea, Republic of

and more 5 locations

Parnaparin vs Aspirin in the Treatment of Retinal Vein Occlusion

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2008-08-12
Last Posted Date
2008-08-12
Lead Sponsor
Università degli Studi dell'Insubria
Target Recruit Count
67
Registration Number
NCT00732927
Locations
🇮🇹

University Of Insubria, Varese, Italy

The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-08-04
Last Posted Date
2020-09-17
Lead Sponsor
University of Vermont
Target Recruit Count
11
Registration Number
NCT00727948
Locations
🇺🇸

University of Vermont, Burlington, Vermont, United States

Chronotherapy with Low-dose Aspirin for Primary Prevention

Phase 4
Active, not recruiting
Conditions
Interventions
First Posted Date
2008-07-30
Last Posted Date
2024-12-06
Lead Sponsor
University of Vigo
Target Recruit Count
3200
Registration Number
NCT00725127
Locations
🇪🇸

CS Friol, Friol, Lugo, Spain

🇪🇸

CS Baiona, Baiona, Pontevedra, Spain

🇪🇸

CS Bueu, Bueu, Pontevedra, Spain

and more 16 locations

The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial

First Posted Date
2008-07-29
Last Posted Date
2011-02-24
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
1000
Registration Number
NCT00724724
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

🇨🇳

General Hospital of Navy, Beijing, Beijing, China

🇨🇳

Beijing Daxing District Hospital, Beijing, Beijing, China

and more 46 locations

Oral Progesterone and Low Dose Aspirin in the Prevention of Preeclampsia

Not Applicable
Terminated
Conditions
Interventions
First Posted Date
2008-07-21
Last Posted Date
2017-04-17
Lead Sponsor
John Uckele
Target Recruit Count
3
Registration Number
NCT00719537
Locations
🇺🇸

William Beaumont Hospital, Royal Oak, Michigan, United States

Patent Foramen Ovale in Cryptogenic Stroke Study

First Posted Date
2008-06-13
Last Posted Date
2011-09-15
Lead Sponsor
Columbia University
Target Recruit Count
630
Registration Number
NCT00697151
Locations
🇺🇸

Columbia College of Physicians and Surgeons, New York, New York, United States

Effects of Omacor and Aspirin on Platelet Function

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2008-06-03
Last Posted Date
2008-06-03
Lead Sponsor
Sanford Research
Target Recruit Count
10
Registration Number
NCT00688961
Locations
🇺🇸

Sanford Research/USD, Sioux Falls, South Dakota, United States

Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination

First Posted Date
2008-06-03
Last Posted Date
2009-03-12
Lead Sponsor
AstraZeneca
Target Recruit Count
84
Registration Number
NCT00688428
© Copyright 2024. All Rights Reserved by MedPath